The increased CXCL10 concentration in VEDOSS patients who progressed vs patients that did not progress to SSc during our observational study supports the notion that a higher Type I IFN or innate immunity drive may be linked to progression to clinically detectable signs. Here, CXCL10 is linked to systemic sclerosis.